Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001349281 | SCV001543616 | benign | not provided | 2022-12-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002476608 | SCV002775214 | uncertain significance | BLOOD GROUP--SWANN SYSTEM; BLOOD GROUP--WALDNER TYPE; BLOOD GROUP--FROESE; BLOOD GROUP--WRIGHT ANTIGEN; Southeast Asian ovalocytosis; Hereditary spherocytosis type 4; BLOOD GROUP--DIEGO SYSTEM; Cryohydrocytosis; Autosomal dominant distal renal tubular acidosis; Renal tubular acidosis, distal, 4, with hemolytic anemia; Malaria, susceptibility to | 2022-01-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003263992 | SCV003946753 | uncertain significance | Inborn genetic diseases | 2023-06-07 | criteria provided, single submitter | clinical testing | The c.1160G>A (p.R387Q) alteration is located in exon 11 (coding exon 10) of the SLC4A1 gene. This alteration results from a G to A substitution at nucleotide position 1160, causing the arginine (R) at amino acid position 387 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |